Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom’s most accurate glucose sensing technology.5 It is specifically designed to provide the 125 million Americans6 ...

will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to ...

Devices compatible with DexCom's G6, G7, or DexCom ONE include Tandem Diabetes Care t:slim X2, Insulet Omnipod 5, some of Eli Lilly's and Novo Nordisk's insulin pens, and the Apple Watch.

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

Securities analysts have also expressed concerns. Baird analyst Jeff Johnson downgraded DexCom on Aug. 5 from "Outperform" to "Neutral" and slashed the price target, citing the company's recent ...

DexCom, Inc. (NASDAQ:DXCM ... for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its ...

Stelo is now part of Dexcom’s overall portfolio of glucose biosensors, with a user base of more than 2.5 million people globally. The Dexcom portfolio in the U.S. consists of the Dexcom G6 and ...

Lastly, DexCom's shares look expensive. DXCM PE Ratio (Forward) data by YCharts. As of this writing, the healthcare industry's average forward price-to-earnings ratio is 19.5. How much will that ...

Lastly, DexCom's shares look expensive. As of this writing, the healthcare industry's average forward price-to-earnings ratio is 19.5. How much will that matter in more than 10 years, though?